D
Donna Badgwell
Researcher at University of Texas MD Anderson Cancer Center
Publications - 17
Citations - 1749
Donna Badgwell is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Ovarian cancer & Biomarker (medicine). The author has an hindex of 12, co-authored 17 publications receiving 1618 citations. Previous affiliations of Donna Badgwell include University of South Florida.
Papers
More filters
Journal ArticleDOI
New tumor markers: CA125 and beyond
Robert C. Bast,Donna Badgwell,Zhimin Lu,Rebecca T. Marquez,Daniel G. Rosen,Jiaxin Liu,Keith A. Baggerly,Edward N. Atkinson,Steven J. Skates,Zhen Zhang,Anna Lokshin,Usha Menon,Ian Jacobs,Karen H. Lu +13 more
TL;DR: CA125 (MUC16) has provided a useful serum tumor marker for monitoring response to chemotherapy, detecting disease recurrence, distinguishing malignant from benign pelvic masses, and potentially improving clinical trial design.
Journal ArticleDOI
Development of a Multimarker Assay for Early Detection of Ovarian Cancer
Zoya R. Yurkovetsky,Steven J. Skates,Aleksey Lomakin,Brian M. Nolen,Trenton C. Pulsipher,Francesmary Modugno,Jeffrey R. Marks,Andrew K. Godwin,Elieser Gorelik,Ian Jacobs,Usha Menon,Karen H. Lu,Donna Badgwell,Robert C. Bast,Anna Lokshin +14 more
TL;DR: A panel of CA-125, HE4, CEA, and VCAM-1, after additional validation, could serve as an initial stage in a screening strategy for epithelial ovarian cancer.
Journal ArticleDOI
Early Detection of Ovarian Cancer
Donna Badgwell,Robert C. Bast +1 more
TL;DR: In this paper, the authors used transvaginal sonography (TVS), serum markers and a combination of the two modalities for early detection of ovarian cancer and achieved a positive predictive value of at least 10%.
Journal ArticleDOI
Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus
Richard G. Moore,A.K. Brown,M. Craig Miller,Donna Badgwell,Zhen Lu,W. Jeffrey Allard,Cornelius O. Granai,Robert C. Bast,Karen H. Lu +8 more
TL;DR: HE4 is elevated in all stages of endometrial can100cer and is more sensitive in early-stageendometrial cancer compared to CA125, and further investigation of HE4 as a marker for early detection of recurrent endometrioid adenocarcinoma of the uterus is warranted.
Book ChapterDOI
Prevention and Early Detection of Ovarian Cancer: Mission Impossible?
Robert C. Bast,Molly Brewer,Changping Zou,Mary A. Hernandez,Mary Daley,Robert Ozols,Karen H. Lu,Zhen Lu,Donna Badgwell,Gordon B. Mills,Steven J. Skates,Zhen Zhang,Dan Chan,Anna Lokshin,Yinhua Yu +14 more
TL;DR: In the future, serum markers should improve the sensitivity of detecting recurrent disease as well as facilitate earlier detection of ovarian cancer, which requires a strategy with high sensitivity and very high specificity to achieve a positive predictive value of 10%.